Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Texas is seeking more than $1 million from Eli Lilly in a lawsuit accusing the drugmaker of persuading physicians to prescribe its medications, including GLP-1s such as Mounjaro and Zepbound, through ...

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Texas Attorney General Ken Paxton is accusing Eli Lilly and Co. of a kickback scheme to induce medical providers to prescribe ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Trump administration demands lower U.S. prices on drugs like Mounjaro, forcing the pharmaceutical company to raise them in ...

An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...

Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how ...